[
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=3bae0a834d9bc3ba955b39fe9b8e71c71fd32cbf10de7475f0637b41775751da",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755794700,
      "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "id": 136514911,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=3bae0a834d9bc3ba955b39fe9b8e71c71fd32cbf10de7475f0637b41775751da"
    }
  },
  {
    "ts": null,
    "headline": "J&J signs $2bn incumbency deal at CDMO Fujifilm’s new hub",
    "summary": "The deal is part of a wider $55bn investment strategy by J&J to bolster US manufacturing amid pressure from Trump.",
    "url": "https://finnhub.io/api/news?id=615a33857129581ee822ff8224aa506412088defdb6ac986dd8c38eca6a1767c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755791935,
      "headline": "J&J signs $2bn incumbency deal at CDMO Fujifilm’s new hub",
      "id": 136467594,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The deal is part of a wider $55bn investment strategy by J&J to bolster US manufacturing amid pressure from Trump.",
      "url": "https://finnhub.io/api/news?id=615a33857129581ee822ff8224aa506412088defdb6ac986dd8c38eca6a1767c"
    }
  },
  {
    "ts": null,
    "headline": "FDA Extends Review Period of REGN's Submission for Eylea HD",
    "summary": "The FDA extends action dates for Regeneron's Eylea HD filings following inspection findings at Catalent Indiana. Nonetheless, Eylea HD remains available through vial administration.",
    "url": "https://finnhub.io/api/news?id=62e9e87bfb47363e507a1f71322aa6455a406eb65f8eb0cf32473121167b88f3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755784260,
      "headline": "FDA Extends Review Period of REGN's Submission for Eylea HD",
      "id": 136468006,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The FDA extends action dates for Regeneron's Eylea HD filings following inspection findings at Catalent Indiana. Nonetheless, Eylea HD remains available through vial administration.",
      "url": "https://finnhub.io/api/news?id=62e9e87bfb47363e507a1f71322aa6455a406eb65f8eb0cf32473121167b88f3"
    }
  },
  {
    "ts": null,
    "headline": "Novo’s facility issues delay FDA decisions on Regeneron’s Eylea HD",
    "summary": "The FDA has confirmed a pushback to target action dates for Eylea HD, a delay expected by Regeneron.",
    "url": "https://finnhub.io/api/news?id=1103633e0273ccdaabc558f8df2aa9d0be0d0cd58f80dd9ba38decc65c3faa9f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755775467,
      "headline": "Novo’s facility issues delay FDA decisions on Regeneron’s Eylea HD",
      "id": 136468007,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The FDA has confirmed a pushback to target action dates for Eylea HD, a delay expected by Regeneron.",
      "url": "https://finnhub.io/api/news?id=1103633e0273ccdaabc558f8df2aa9d0be0d0cd58f80dd9ba38decc65c3faa9f"
    }
  },
  {
    "ts": null,
    "headline": "J&J to invest $2 billion to boost US manufacturing as drug tariffs loom",
    "summary": "Major drugmakers, including Eli Lilly and AstraZeneca, have also committed to shell out billions of dollars to scale up their U.S. footprint in response to Trump's efforts, including tariff threats.  Earlier this month, Trump said he plans to impose phased-in tariffs for the pharmaceutical sector, which could start small and eventually rise to 250%.  J&J said on Thursday it has reached a 10-year agreement with Tokyo-based contract drug developer Fujifilm Diosynth for its more than 160,000-square-foot manufacturing facility in Holly Springs, North Carolina, which would create about 120 new jobs.",
    "url": "https://finnhub.io/api/news?id=093db7c7a1b83ad1398220f60d69b3878fd633e0969b620640780f2618e5c318",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755767496,
      "headline": "J&J to invest $2 billion to boost US manufacturing as drug tariffs loom",
      "id": 136452214,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Major drugmakers, including Eli Lilly and AstraZeneca, have also committed to shell out billions of dollars to scale up their U.S. footprint in response to Trump's efforts, including tariff threats.  Earlier this month, Trump said he plans to impose phased-in tariffs for the pharmaceutical sector, which could start small and eventually rise to 250%.  J&J said on Thursday it has reached a 10-year agreement with Tokyo-based contract drug developer Fujifilm Diosynth for its more than 160,000-square-foot manufacturing facility in Holly Springs, North Carolina, which would create about 120 new jobs.",
      "url": "https://finnhub.io/api/news?id=093db7c7a1b83ad1398220f60d69b3878fd633e0969b620640780f2618e5c318"
    }
  }
]